Evaluation of efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration

Evaluation of efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration - Efficacy of topical bromfenac for exudative age-related macular degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002854

Enrollment

Registered

2009-12-07

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

exudative age-related macular degeneration

Interventions

topical bromfenac as an adjunctive therapy to intravitreal injection of ranibizumab topical artificail tears as the sham of blomfenac to intravitreal injection of ranibizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: treatment naive age-related macular degeneration with subfoveal choroidal neovascularization with visual acuity from 0.1 to 0.8

Exclusion criteria

Exclusion criteria: choroidal neovascularization secondary to pathorogical myopia or other diseases

Design outcomes

Primary

Measure	Time frame
total number of injections of ranibizumab during 6 months' follow-up	—

Secondary

Measure	Time frame
the rate of eyes with persistent leakage from choroidal neovascularization on fluorescein angiography	—

Countries

Japan

Contacts

Public ContactFumi Gomi

Osaka University Medical School Dept. of Ophthalmology

fgomi@ophthal.med.osaka-u.ac.jp06-6879-3456

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026